Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
16.24
-0.18 (-1.10%)
At close: Dec 31, 2025, 4:00 PM EST
16.00
-0.24 (-1.48%)
After-hours: Dec 31, 2025, 7:11 PM EST
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $93.97M in the quarter ending September 30, 2025, with 102.38% growth. This brings the company's revenue in the last twelve months to $252.75M, up 42.57% year-over-year. In the year 2024, Adaptive Biotechnologies had annual revenue of $178.96M with 5.10% growth.
Revenue (ttm)
$252.75M
Revenue Growth
+42.57%
P/S Ratio
9.66
Revenue / Employee
$408,326
Employees
619
Market Cap
2.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADPT News
- 2 days ago - Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Reuters
- 17 days ago - Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - GlobeNewsWire
- 23 days ago - Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - GlobeNewsWire
- 26 days ago - Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - GlobeNewsWire
- 27 days ago - Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
- 5 weeks ago - Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - GlobeNewsWire